Free Trial
NASDAQ:ERNA

Ernexa Therapeutics 3/14/2024 Earnings Report

Ernexa Therapeutics logo
$1.37 +0.06 (+4.58%)
Closing price 10/8/2025 04:00 PM Eastern
Extended Trading
$1.37 0.00 (0.00%)
As of 07:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ernexa Therapeutics EPS Results

Actual EPS
-$17.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ernexa Therapeutics Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ernexa Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Ernexa Therapeutics' next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules.

Conference Call Resources

Ernexa Therapeutics Earnings Headlines

Ernexa Therapeutics' (ERNA) "Sell (E+)" Rating Reiterated at Weiss Ratings
Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 3.7% - Time to Sell?
Your Chance Before Wall Street Moves
By the time Wall Street analysts catch on, the biggest gains are usually gone. The real profits often happen before the IPO, when private investors are buying in at a fraction of the price. Our new report, From Private to Public: How To Invest In Companies Before They IPO, shows you how to identify these deals and evaluate if they’re worth the risk.tc pixel
See More Ernexa Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ernexa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ernexa Therapeutics and other key companies, straight to your email.

About Ernexa Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

View Ernexa Therapeutics Profile

More Earnings Resources from MarketBeat